Australian & New Zealand Thyroid Cancer Registry 2018 Annual Report

Liane Ioannou, Jonathan Serpell, Elysia Greenhill, Julie A Miller, Cino Bendinelli, Jenny Gough, Dean Lisewski, Win Meyer-Rochow, Stan Sidhu, Duncan Topliss, David Walters, John Zalcberg, Madeleine Allnutt, Chhavi Bhatt, Susannah Ahern

Research output: Book/ReportOther ReportOtherpeer-review

Abstract

The occurrence of thyroid cancer is increasing throughout the developed world and since the 1990s has become the fastest increasing malignancy. Between 1991 and 2009, the number of thyroid cancer cases increased by 250% in Australia. The most common types of thyroid cancer have very good long-term prognoses, and of all non-cutaneous cancers, thyroid cancer has the highest five-year survival rate at 98% .
However, there are significant variations in the management, treatment and outcomes of thyroid cancer, particularly in diagnostic investigations undertaken; optimal extent of surgery; use of active surveillance; role of lymph node dissections; complication rates following surgery; postsurgical hormone treatment, calcium and vitamin D therapy; and radioactive iodine treatment.
While thyroid cancer management is informed by well-regarded international guidelines, there is a lack of population-level data regarding patient outcomes from thyroid cancer in Australia and New Zealand. Therefore it is likely that there is clinician variation in adherence to best practice and therefore, individual patient outcomes of thyroid cancer. In addition, while detailed guidelines exist, there remain questions regarding optimal management of patient sub-populations.
A proven strategy to reduce variation in outcomes is to measure and compare high quality disease-specific data using clinical quality registries (CQRs). CQRs provide the most effective means of collecting high quality data and are a tool for quality improvement. The Australian Commission on Safety and Quality in Health Care (ACSQHC) has advocated development of CQRs, particularly in key high burden areas including cancers.

Original languageEnglish
Place of PublicationMelbourne, Australia
PublisherMonash University
Number of pages24
Volume1
Publication statusPublished - 13 Jan 2019

Keywords

  • thyroid cancer
  • CQRs

Cite this

Ioannou, L., Serpell, J., Greenhill, E., Miller, J. A., Bendinelli, C., Gough, J., ... Ahern, S. (2019). Australian & New Zealand Thyroid Cancer Registry 2018 Annual Report. Melbourne, Australia: Monash University.
Ioannou, Liane ; Serpell, Jonathan ; Greenhill, Elysia ; Miller, Julie A ; Bendinelli, Cino ; Gough, Jenny ; Lisewski, Dean ; Meyer-Rochow, Win ; Sidhu, Stan ; Topliss, Duncan ; Walters, David ; Zalcberg, John ; Allnutt, Madeleine ; Bhatt, Chhavi ; Ahern, Susannah. / Australian & New Zealand Thyroid Cancer Registry 2018 Annual Report. Melbourne, Australia : Monash University, 2019. 24 p.
@book{e6bd4dde298f49ad94645fb237efed62,
title = "Australian & New Zealand Thyroid Cancer Registry 2018 Annual Report",
abstract = "The occurrence of thyroid cancer is increasing throughout the developed world and since the 1990s has become the fastest increasing malignancy. Between 1991 and 2009, the number of thyroid cancer cases increased by 250{\%} in Australia. The most common types of thyroid cancer have very good long-term prognoses, and of all non-cutaneous cancers, thyroid cancer has the highest five-year survival rate at 98{\%} .However, there are significant variations in the management, treatment and outcomes of thyroid cancer, particularly in diagnostic investigations undertaken; optimal extent of surgery; use of active surveillance; role of lymph node dissections; complication rates following surgery; postsurgical hormone treatment, calcium and vitamin D therapy; and radioactive iodine treatment.While thyroid cancer management is informed by well-regarded international guidelines, there is a lack of population-level data regarding patient outcomes from thyroid cancer in Australia and New Zealand. Therefore it is likely that there is clinician variation in adherence to best practice and therefore, individual patient outcomes of thyroid cancer. In addition, while detailed guidelines exist, there remain questions regarding optimal management of patient sub-populations.A proven strategy to reduce variation in outcomes is to measure and compare high quality disease-specific data using clinical quality registries (CQRs). CQRs provide the most effective means of collecting high quality data and are a tool for quality improvement. The Australian Commission on Safety and Quality in Health Care (ACSQHC) has advocated development of CQRs, particularly in key high burden areas including cancers.",
keywords = "thyroid cancer, CQRs",
author = "Liane Ioannou and Jonathan Serpell and Elysia Greenhill and Miller, {Julie A} and Cino Bendinelli and Jenny Gough and Dean Lisewski and Win Meyer-Rochow and Stan Sidhu and Duncan Topliss and David Walters and John Zalcberg and Madeleine Allnutt and Chhavi Bhatt and Susannah Ahern",
year = "2019",
month = "1",
day = "13",
language = "English",
volume = "1",
publisher = "Monash University",

}

Ioannou, L, Serpell, J, Greenhill, E, Miller, JA, Bendinelli, C, Gough, J, Lisewski, D, Meyer-Rochow, W, Sidhu, S, Topliss, D, Walters, D, Zalcberg, J, Allnutt, M, Bhatt, C & Ahern, S 2019, Australian & New Zealand Thyroid Cancer Registry 2018 Annual Report. vol. 1, Monash University, Melbourne, Australia.

Australian & New Zealand Thyroid Cancer Registry 2018 Annual Report. / Ioannou, Liane; Serpell, Jonathan; Greenhill, Elysia; Miller, Julie A; Bendinelli, Cino; Gough, Jenny; Lisewski, Dean; Meyer-Rochow, Win; Sidhu, Stan; Topliss, Duncan; Walters, David; Zalcberg, John; Allnutt, Madeleine; Bhatt, Chhavi; Ahern, Susannah.

Melbourne, Australia : Monash University, 2019. 24 p.

Research output: Book/ReportOther ReportOtherpeer-review

TY - BOOK

T1 - Australian & New Zealand Thyroid Cancer Registry 2018 Annual Report

AU - Ioannou, Liane

AU - Serpell, Jonathan

AU - Greenhill, Elysia

AU - Miller, Julie A

AU - Bendinelli, Cino

AU - Gough, Jenny

AU - Lisewski, Dean

AU - Meyer-Rochow, Win

AU - Sidhu, Stan

AU - Topliss, Duncan

AU - Walters, David

AU - Zalcberg, John

AU - Allnutt, Madeleine

AU - Bhatt, Chhavi

AU - Ahern, Susannah

PY - 2019/1/13

Y1 - 2019/1/13

N2 - The occurrence of thyroid cancer is increasing throughout the developed world and since the 1990s has become the fastest increasing malignancy. Between 1991 and 2009, the number of thyroid cancer cases increased by 250% in Australia. The most common types of thyroid cancer have very good long-term prognoses, and of all non-cutaneous cancers, thyroid cancer has the highest five-year survival rate at 98% .However, there are significant variations in the management, treatment and outcomes of thyroid cancer, particularly in diagnostic investigations undertaken; optimal extent of surgery; use of active surveillance; role of lymph node dissections; complication rates following surgery; postsurgical hormone treatment, calcium and vitamin D therapy; and radioactive iodine treatment.While thyroid cancer management is informed by well-regarded international guidelines, there is a lack of population-level data regarding patient outcomes from thyroid cancer in Australia and New Zealand. Therefore it is likely that there is clinician variation in adherence to best practice and therefore, individual patient outcomes of thyroid cancer. In addition, while detailed guidelines exist, there remain questions regarding optimal management of patient sub-populations.A proven strategy to reduce variation in outcomes is to measure and compare high quality disease-specific data using clinical quality registries (CQRs). CQRs provide the most effective means of collecting high quality data and are a tool for quality improvement. The Australian Commission on Safety and Quality in Health Care (ACSQHC) has advocated development of CQRs, particularly in key high burden areas including cancers.

AB - The occurrence of thyroid cancer is increasing throughout the developed world and since the 1990s has become the fastest increasing malignancy. Between 1991 and 2009, the number of thyroid cancer cases increased by 250% in Australia. The most common types of thyroid cancer have very good long-term prognoses, and of all non-cutaneous cancers, thyroid cancer has the highest five-year survival rate at 98% .However, there are significant variations in the management, treatment and outcomes of thyroid cancer, particularly in diagnostic investigations undertaken; optimal extent of surgery; use of active surveillance; role of lymph node dissections; complication rates following surgery; postsurgical hormone treatment, calcium and vitamin D therapy; and radioactive iodine treatment.While thyroid cancer management is informed by well-regarded international guidelines, there is a lack of population-level data regarding patient outcomes from thyroid cancer in Australia and New Zealand. Therefore it is likely that there is clinician variation in adherence to best practice and therefore, individual patient outcomes of thyroid cancer. In addition, while detailed guidelines exist, there remain questions regarding optimal management of patient sub-populations.A proven strategy to reduce variation in outcomes is to measure and compare high quality disease-specific data using clinical quality registries (CQRs). CQRs provide the most effective means of collecting high quality data and are a tool for quality improvement. The Australian Commission on Safety and Quality in Health Care (ACSQHC) has advocated development of CQRs, particularly in key high burden areas including cancers.

KW - thyroid cancer

KW - CQRs

M3 - Other Report

VL - 1

BT - Australian & New Zealand Thyroid Cancer Registry 2018 Annual Report

PB - Monash University

CY - Melbourne, Australia

ER -

Ioannou L, Serpell J, Greenhill E, Miller JA, Bendinelli C, Gough J et al. Australian & New Zealand Thyroid Cancer Registry 2018 Annual Report. Melbourne, Australia: Monash University, 2019. 24 p.